
Sign up to save your podcasts
Or


A groundbreaking clinical study on patients with HER2-low breast cancer may impact they way we provide treatment. Dr. David Cameron from the University of Edinburgh in Scotland joins Dr. Pavanai Chalasani to share key results from the DESTINY Breast04 trial.
By ReachMD4.5
22 ratings
A groundbreaking clinical study on patients with HER2-low breast cancer may impact they way we provide treatment. Dr. David Cameron from the University of Edinburgh in Scotland joins Dr. Pavanai Chalasani to share key results from the DESTINY Breast04 trial.

39 Listeners

10 Listeners

59 Listeners

1,145 Listeners

195 Listeners

45 Listeners

7 Listeners